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Leptin plays a central role in the regulation of fatty acid homeostasis, promoting lipid storage in adipose tissue and fatty acid oxidation in
peripheral tissues. Loss of leptin signaling leads to accumulation of lipids in muscle and loss of insulin sensitivity secondary to obesity. In this
study, we examined the direct and indirect effects of leptin signaling on mitochondrial enzymes including those essential for peripheral fatty
acid oxidation. We assessed the impact of leptin using the JCR:LA-cp rat, which lacks functional leptin receptors. The activities of marker
mitochondrial enzymes citrate synthase (CS) and cytochrome oxidase (COX) were similar between wild-type (+/?) and corpulent (cp/cp) rats.
In contrast, several tissues showed variations in the fatty acid oxidizing enzymes carnitine palmitoyltransferase II (CPT II), long-chain acyl-
CoA dehydrogenase (LCAD) and 3-hydroxyacyl-CoA dehydrogenase (HOAD). It was not clear if these changes were due to loss of leptin
signaling or to insulin insensitivity. Consequently, we examined the effects of leptin on cultured C2C12 and Sol8 cells. Leptin (3 days at 0,
0.2, or 2.0 nM) had no direct effect on the activities of CS, COX, or fatty acid oxidizing enzymes. Leptin treatment did not affect luciferase-
based reporter genes under the control of transcription factors involved in mitochondrial biogenesis (nuclear respiratory factor-1 (NRF-1),
nuclear respiratory factor-2 (NRF-2)) or fatty acid enzyme expression (peroxisome proliferator-activated receptors (PPARs)). These studies
suggest that leptin exerts only indirect effects on mitochondrial gene expression in muscle, possibly arising from insulin resistance.
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Leptin is a peptide hormone that controls whole-body
lipid metabolism with regulatory influences on fatty acid
homeostasis in multiple tissues. In storage tissues, such as
adipose, leptin promotes triacylglyceride (TAG) storage,
whereas in peripheral tissues, such as skeletal muscle, leptin
enhances lipid oxidation [1–3]. Models with defects in
leptin signaling show pronounced changes in whole-body
metabolism, including obesity, insulin resistance and car-
diovascular pathologies [4–8]. The JCR:LA rat model, used
in the present study, possesses an autosomal recessive
mutation in the leptin receptor gene (cp) that disrupts the
extracellular domain of the leptin receptor. Homozygous cp/0925-4439/$ - see front matter D 2003 Published by Elsevier B.V.
doi:10.1016/j.bbadis.2003.10.006
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Main St. West, Hamilton, ON, Canada L8S 4K1.cp rats become obese and insulin-resistant, whereas homo-
zygous wild-type (+/+) or heterozygotes (+/cp) (collectively
+/?) are lean and metabolically normal. By 4 weeks of age,
cp/cp rats show skeletal TAG levels that are elevated by
more than 4-fold but insulin levels remain normal. After 6
weeks of age, the obese phenotype emerges. While plasma
glucose remains constant (10 mM), cp/cp rats show
increases in plasma fatty acids (0.37 vs. 0.27 mM), plasma
TAG (6 vs. 2 mM) [6], and soleus muscle TAG (160 vs. 40
mmol/g) [4]. The cp/cp rats have 10-fold higher insulin
levels (2746 vs. 272 pM) and insulin resistance in muscle
[4,6]. The complex metabolic phenotype arises from the
primary lesion (i.e. loss of leptin signaling) in addition to
secondary effects from hyperphagia, hyperlipidemia and
insulin resistance [4–8].
Despite the importance of muscle in whole-body lipid
metabolism, the direct effects of leptin on the muscle
metabolic phenotype remain poorly understood. In particu-
lar, little is known about how leptin influences the expres-
sion of the mitochondrial genes that encode the enzymes
responsible for lipid oxidation and energy metabolism.
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leptin infusion, activating JAK and PI3K pathways [9].
Muscle also activates AMP-activated kinase (AMPK) in
response to leptin [10,11], enhancing fatty acid oxidation
through effects on acetyl-CoA carboxylase (ACC) [12].
However, chronic leptin treatment of rats did not alter the
activities of either citrate synthase (CS) or h-hydroxyacyl-
CoA dehydrogenase (HOAD) in soleus muscle [13]. Micro-
array analyses identify few genes in muscle that are
influenced by leptin treatment [14]. Leptin treatments of
whole animals lead to an increase in muscle UCP3 levels
and increases in proton leak, although it is likely that the
effects are indirect [15].
Despite recent advances in understanding leptin signal
transduction (see Ref. [16]) and respiratory gene expression
(see Ref. [17]) relatively few studies have considered
interaction between the two pathways. Signaling via the
leptin receptor can involve the JAK/STAT [18,19] as well as
the p38- and ERK–MAPK pathways [19–21]. Mitochon-
drial gene expression is regulated by a number of transcrip-
tional regulators. Nuclear respiratory factor (NRF)-1 and
NRF-2 appear to regulate the enzymes of oxidative phos-
phorylation [22], whereas the fatty acid oxidizing enzymes
are regulated by peroxisome proliferator-activated receptors
(PPARs) [23]. PPAR appears to mediate changes in fatty
acid enzymes in response to diet and food deprivation
[24,25]. In addition, the co-activator PPAR-gamma coacti-
vator-1 (PGC-1) interacts with PPARs and NRF-1 [26].
While there is potential for cross-talk between leptin sig-
naling and mitochondrial gene expression, the connections
have not been explored.
In this study, we assessed the effects of leptin on the
expression and activity of the enzymes of fatty acid oxida-
tion and mitochondrial metabolism using a combination of
in vitro and in vivo models. Cultured rodent myoblasts were
used to explore potential direct effects of leptin on mito-
chondrial gene expression and transcriptional control. We
also assessed the changes in bioenergetic enzymes seen in
JCR:LA rats tissues, including multiple striated muscle fiber
types. While the JCR:LA corpulent rat showed changes in
the levels of several bioenergetic enzymes, we found no
evidence for direct effects of leptin on the expression of
mitochondrial enzymes in muscle.2. Methods
2.1. Animals
Tissues were collected from JCR:LA-cp rats in accor-
dance with CCAC guidelines and with the approval of
animal care of the University of Alberta. Male rats, cp/cp
(obese, 497F 13 g) or +/? (lean, 317F 9 g) were bred in the
established colony at the University of Alberta. At 12 weeks
of age, six animals from each group were euthanized and
individual skeletal muscles, liver, and heart were extractedand immediately placed in liquid N2 and stored at  80 jC
until analysis.
2.2. Cell culture
All cell culture media and sera were supplied by GIBCO.
Cells were grown at 37 jC in 10% CO2. Penicillin,
streptomycin, and neomycin (PSN) were included in all
media, which was refreshed every 3 days. Sol8 cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM; 25
mM glucose, 4 mM glutamine, and 1 mM pyruvate)
supplemented with 20% fetal bovine serum (FBS). C2C12
cells were grown in DMEM supplemented with 10% FBS.
Once cells had reached 90% confluency, the medium was
changed to DMEM supplemented with 2% horse serum
(HS) with 0, 0.2, or 2 nM recombinant rat leptin (R&D
Systems Inc., Minneapolis, MN) refreshed daily for 3 days.
2.3. Enzyme activities
Tissue homogenates of soleus, tibialis anterior (TA),
gastrocnemius (gastroc), liver, and heart were prepared by
powdering in liquid N2 and weighing out approximately
50–100 mg of tissue. To this, 20 volumes of extraction
buffer consisting of 20 mM Hepes (pH 7.4), 1 mM EDTA
and 0.1% Triton X-100 was added. C2C12 and Sol8 cells
were harvested in extraction buffer to yield approximately 1
mg protein/ml. Citrate synthase (EC 4.1.3.7), HOAD (EC
1.1.1.35) and cytochrome oxidase (COX, EC 1.9.3.1) were
assayed as previously described [27], except HOAD was
assayed in 50 mM imidazole buffer (pH 7.2). Long-chain
acyl-CoA dehydrogenase (LCAD, EC 1.3.99.13) was
assayed according to Davidson and Schulz [28] in 0.1 M
potassium phosphate buffer containing 28 AM 2,6-dichlor-
ophenolindophenol (DCPIP), 0.65 mM phenazine metho-
sulfate (PMS), 0.2 mM N-ethylmaleimide and 0.45 mM
KCN. The reaction was started with the addition of 0.1 mM
palmitoyl-CoA. Carnitine palmitoyltransferase II (CPT II,
EC 2.3.1.21) was assayed in 20 mM Tris buffer (pH 8.0)
containing 0.1 mM DTNB and 5 mM L-carnitine. The
reaction was started with the addition of 0.1 mM palmi-
toyl-CoA. This activity represents CPT II activity and was
completely insensitive to malonyl-CoA inhibition since
CPT I activity is inactivated by freezing [29] and detergent
treatment [30]. Protein concentrations were determined by
the Bradford method (Biorad). All assays were performed at
37 jC on a SpectraMAX Plus spectrophotometer (Molecu-
lar Devices).
2.4. Northern analysis
Total RNA was purified from rat tissues and cell culture
from guanidinium thiocyanate (GTC) extracts [27]. RNA
was electrophoresed on 1% agarose/2% formaldehyde gels.
cDNA probes for CS and HOAD were obtained by PCR as
previously described [27]. Probes for CPT Ia, CPT II,
Table 1
Primer sequences and response elements used for cDNA probe and luciferase reporter construct production via PCR from rat ventricle cDNA produced from
total RNA
Gene Forward primer (5V–3V) Reverse primer (5V–3)V Annealing temperature (jC) Size (bp)
PGC-1 gtggatgaagacggattgccc cctgcagttccagagagttcc 55 601
CPT Ih gcaaactggaccgagaagag aagaaagcagcacgttcgat 54 397
CPT II agacgctcagcttcaacctc ccatmgctgcytctttggt 54 409
LCAD tggcattagcctctttttgg tggatgtgtgcgactgtttt 51 300
hCS promoter aaaacgcgtgctttccaattgcccttatagc ttttctcgaggcgggcgatctccgggatc 64 2113
Response element
NRF-1 gtacctagtgcgcacgcgcaggatagtgcgcacgcgcaggatagtgcgcacgcgcaggataggtgcgcacgcgcagg
NRF-2 caccggaagagaccggaagagaccggaagagaccggaagagggagagct
Binding site sequences are underlined.
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cDNA with primers outlined in Table 1. PCR fragments
were cloned into PCR 2.1-TOPO (Invitrogen) and trans-
formed into XL-1 Blue E. coli cells. Probe identities were
confirmed by sequencing (Cortec, Inc., Kingston, Canada).
The cDNA probes (50 ng) were labeled with 50 ACi of
[a-32P] dCTP using Ready-to-Go DNA labeling beads
(Amersham Pharmacia Biotech Inc.) and signals were
measured using a phosphoimager and quantified using
Imagequant software (Molecular Dynamics).
2.5. Plasmids and constructs
To generate citrate synthase promotor (pGL2-hCS), 2113
bp upstream of the human citrate synthase (hCS) translation
initiation start site was amplified from human genomic
DNA by PCR with restriction sites introduced using primers
in Table 1. The resulting PCR product was cloned into the
firefly luciferase reporter vector (pGL2-basic, Promega)
using the MluI and XhoI restriction sites.
The NRF1-TKLuc plasmid is a reporter construct that
contains four tandem copies of the mouse mitochondrial
RNA processing RNA promoter’s NRF-1 binding site [31]
(underlined in Table 1) cloned into KpnI and SacI sites in
TKLuc. TKLuc contains the 757 bp HSV (thymadine kinase)
TK promoter fragment digested from pRL-TK (Promega) at
the BglII and HindIII sites, and subcloned into pGL2-basicTable 2
Enzyme activities of liver, heart, gastrocnemius (gastroc), tibialis anterior (TA) an
COX CS LDH
Liver +/? 27F 2 17F 1 796F
cp/cp 27F 1 19F 1 1272F
Heart +/? 73F 4 133F 8 509F
cp/cp 73F 5 140F 1 646F
Gastroc +/? 14F 3 24F 1 1110F
cp/cp 16F 1 27F 1* 1181F
TA +/? 9F 1 38F 3 1353F
cp/cp 14F 2 40F 2 1530F
Soleus +/? 6.3F 0.4 24F 1 178F
cp/cp 7.1F 0.8 29F 1 207F
Values are meansF S.E. of n= 6 expressed as Amol substrate converted min 1 g
*Significantly different from +/?, P< 0.05.(Promega). The NRF2-TKLuc reporter consists of four
tandem copies of the NRF-2 response element [32], cloned
into KpnI and SacI sites in TKLuc. Reporter constructs for
PPARa response element PPRE-TKLuc derived from perox-
isomal acyl-CoA oxidase gene promotor were a gift from D.
Kelly (Washington University) [33]. The Renilla luciferase
reporter construct, pRL-TK (Promega), was used as a
cotransfection control for transfection efficiency.
2.6. Transfections
Plasmids were prepared for transfection using Maxi Prep
kit (Qiagen). Cells were transfected using FuGENE 6
(Roche) as per the manufacturer’s protocol. Cells were
grown to f 50% confluence in 24-well cell culture plates
then transfected with fresh growth medium containing 250
ng of firefly luciferase plasmid (test plasmid) in combination
with 50 ng Renilla luciferase plasmid (control plasmid, pRL-
TK, Promega).
2.7. Luciferase measurements
Cells were harvested and frozen 3 days post-differentia-
tion in 100 Al 1 passive lysis buffer (PLB, Promega).
Thawed lysates were assayed on a Lmax Luminometer
(Molecular Devices) using the automatic injector. To mea-
sure firefly luciferase, 100 Al of luciferase assay reagentd soleus muscle from obese (cp/cp) and lean (+/?) JCR:LA-cp rats
CPT II HOAD LCAD
45 1.1F 0.03 75F 3 1.1F 0.06
71* 1.6F 0.2* 84F 6 1.2F 0.1
22 2.0F 0.2 42F 6 1.8F 0.1
18* 2.7F 0.3 55F 6 2.0F 0.02
95 0.43F 0.02 4.4F 0.4 0.46F 0.05
126 0.56F 0.05* 4.5F 0.2 0.62F 0.05*
121 0.60F 0.06 3.7F 0.2 0.44F 0.04
56 0.63F 0.04 5.3F 0.4* 0.52F 0.06
7 1.3F 0.2 7.0F 0.5 0.98F 0.06
12 1.6F 0.2 9.5F 0.7* 1.02F 0.05
tissue wet weight 1.
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cell lysate in a 96-well plate. Relative light units (RLUs)
were measured for 10 s, with a 2-s pre-measurement delay.
Then the LARII luminescence was quenched and Renilla
luciferase activity measured by adding 100 Al of Stop &
Glow solution (Promega) to the same well. RLUs were
again measured for 10 s, with a 2-s delay. Values of
reporters are standardized relative to Renilla luciferase
values.
2.8. Statistical analysis
All data presented are meansF S.E. Results were ana-
lyzed using a t-test, one-way and two-way ANOVA (JMP
Statistical Software, SAS Institute Inc.).Fig. 1. Northern analysis of the JCR:LA-cp rat (A) TA and (B) heart muscle
in cp/cp relative to wild-type (+/?) controls. Hybridization was with cDNA
probes for CPT Ih, CPT II, LCAD, HOAD, CS and PGC-1. N= 6.3. Results
3.1. Enzyme activities
The apparent Vmax values for COX, CS, HOAD, LCAD,
CPTII and LDH from several skeletal muscles, heart and
liver appear in Table 2. There was no significant change in
COX or CS activities, with the exception of the gastrocne-
mius muscle (CS + 13%), in cp/cp rats. The cp/cp rats did
show significantly (P < 0.05) greater activity of CPT II
( + 45% in liver and + 30% in gastroc), HOAD ( + 43% in
TA and + 36% in sol) and LCAD ( + 35% in gastrocnemius)
in peripheral tissues. The activity of LDH was elevated in
both the heart ( + 27%) and the liver ( + 60%) of cp/cp rats.
C2C12 and Sol8 cell lines were induced to differentiate by
serum starvation and treated with leptin at 0, 0.2, or 2.0 nM.
After 3 days of differentiation, there was no effect of leptin
on the activities of COX, CS, HOAD or LCAD in either cell
line (Table 3).
3.2. Changes in mRNA
Northern analysis was conducted on heart and TAmuscles
to assess the pattern of mRNA for selected enzymes. There
were no differences between genotypes in CS mRNA in
either TA or heart (Fig. 1A and B). In TA muscle, the cp/cpTable 3
Enzyme activities of C2C12 and Sol8 cells measured after 3 days of
differentiation with and without leptin
Leptin (nM) COX CS HOAD LCAD
C2C12 0 43F 2 51F1 29F 1 1.7F 0.3
0.2 42F 2 53F 3 28F 2 1.9F 0.4
2.0 50F 2 53F 2 29F 2 2.0F 0.5
Sol8 0 66F 5 56F 6 30F 3 1.4F 0.3
0.2 66F 3 60F 5 30F 5 1.3F 0.4
2.0 67F 4 53F 3 32F 4 1.4F 0.1
Values are meansF S.E. of n= 3 expressed as Amol substrate converted
min 1 mg cellular protein 1.
Fig. 2. Northern analysis for (A) C2C12 and (B) Sol8 cell lines treated with
0, 0.2 and 2 nM recombinant rat leptin. Hybridization was with cDNA
probes for LCAD, HOAD, UCP-2, and CS (N= 3).
Fig. 3. Transient transfections of C2C12 cells with luciferase reporter
constructs for PPAR, NRF-1, NRF-2, and CS. TK was used as a basal
promoter. Cells were allowed to differentiate for 3 days in media containing
either 0.2 or 2 nM recombinant rat leptin. N = 3.
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( + 29%) and HOAD ( + 20%) (P < 0.05). In TAmuscle PGC-
1 (P= 0.09) and CPT Ih (P= 0.12) mRNA levels appeared to
increase but not to a level that was significantly different than
controls (Fig. 1A). There were no significant differences in
mRNA levels for the genes of interest in heart compared to
controls (Fig. 1B).
In the cell culture models (C2C12 and Sol8), there was no
significant effect of the leptin treatments on mRNA levels of
LCAD, HOAD or CS (Fig. 2A and B). There was a
significant decrease in UCP2 ( 26%) mRNA in Sol8 cells
at leptin concentration of 2.0 nM.
3.3. Reporter gene analysis
C2C12 cells were transiently transfected with luciferase
reporters for PPAR, NRF-1, NRF-2 and human CS promot-
er. Treatment of differentiated cells with 0.2 (Fig. 3A) and 2
nM (Fig. 3B) leptin had no significant effect on the
transcription of these reporters.4. Discussion
4.1. Leptin signaling and gene expression
Our analysis of leptin-treated cultured myocytes was
used to assess the potential for direct effects of leptin.
Murine myocytes possess the leptin receptor [20]. Treatment
of cultured muscle cells (C2C12 and Sol8) with leptin failed
to induce any changes in gene expression. There were no
changes in the activities of mitochondrial enzymes, includ-
ing those involved in fatty acid oxidation (Table 3). Simi-
larly, there were no differences in mRNA for selected
enzymes (LCAD, HOAD, CS). There was an apparent
decrease in mRNA for UCP2 in Sol8 cells.
Recent studies have shown that the JAK/STAT pathway
in muscles can respond within minutes to changes in leptin
levels [9]. In contrast, we found that 3 days of treatment
with leptin failed to induce any change in transcription
factor reporter genes. Leptin did not alter the activity ofreporter genes for NRF-1 and NRF-2, which control the
expression of many mitochondrial genes that are induced
with adaptive remodeling of mitochondria [17,22,31]. Sim-
ilarly, the activity of a reporter gene driven by a complex
promoter from the CS gene was unresponsive to leptin (Fig.
3). Similarly, the activity of the PPAR reporter was un-
changed by leptin (Fig. 3). In other experimental contexts,
these reporters increase several fold in response to hormone
treatment. Vega et al. (e.g. Ref. [33]) have used the PPAR
construct to show the responses to PPAR agonists. Similar-
ly, we have found that the NRF-1, NRF-2 and CS constructs
increase in activity 5–10-fold with cellular differentiation
(unpublished). Thus, the results argue that leptin does not
affect gene expression in these cells.
4.2. Metabolic phenotype of the JCR:LA corpulent rat
The results from in vitro studies failed to find support for
any effects of leptin on the expression of mitochondrial
genes. However, when mitochondrial enzyme activities and
mRNA levels were assessing the JCR:LA rats, which are
deficient in leptin signaling, we saw a complex pattern of
changes. It is important to stress that the enzyme changes
(activity and mRNA) in this model could, in principle, be
due to (i) the primary mutation in the gene for the leptin
receptor, (ii) the compensatory changes in insulin signaling,
or (iii) changes in metabolite/nutrient regulation. When we
compared the enzyme activities between cp/cp and +/?
littermates, there were no detectable changes in the activities
of select citric acid cycle (CS) and electron transport chain
(COX) enzymes. This is consistent with what we observed
in vitro. Similarly, no changes in CS were seen when rats
were treated directly with leptin [13]. However, when other
enzymes were analyzed, we saw complex changes in
enzyme/mRNA levels and stoichiometries.
Under most conditions, the genes of fatty acid oxidation
are regulated in parallel allowing tissues to retain intrinsic
stoichiometries [34,35]. However, the cp/cp genotype caused
complex changes in fatty acid oxidation enzyme patterns in
different tissues. The activities of HOAD were elevated in
TA and soleus but not liver, heart or gastrocnemius. The
activities of CPT II were elevated in liver and gastrocnemius
but not the other tissues. LCAD activities were increased
only in gastrocnemius. In TA muscle, the pattern of change
in mRNA reflected the changes in enzyme activity, sug-
gested that the changes were controlled by transcription.
Several studies have implicated PGC-1 in the coordination of
changes in mitochondrial gene expression in relation to
diabetes and obesity [33]. However, we found no significant
change in the mRNA levels of PGC-1. The non-stoichio-
metric changes in the different muscles and other tissues are
likely due to tissue specific peculiarities in the control of
gene expression.
Another enzyme that appears to respond differently in
each tissue was LDH. It was elevated in heart and liver of
cp/cp rats but not the skeletal muscles. Consistent with our
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activity than caloric-restricted rats [36]. The functional
significance of elevated LDH depends on which intracellu-
lar pool has increased [37,38], and to a lesser extent, any
change in isozyme composition [39]. The increases in heart
LDH likely arose through effects on expression of the LDH-
B gene. Conversely, the increases in liver LDH likely arose
through effects on the LDH-A gene. Surprisingly little is
known about the control of the LDH gene expression. LDH
activities, which can be diagnostic indicators of liver and
heart disease [40], are generally thought to contribute to
nutrient sensing pathways that balance glycolytic and oxi-
dative metabolism [41].
The importance of leptin itself in the metabolic pheno-
type of cp/cp rats is difficult to assess because of confound-
ing effects on insulin levels and insulin sensitivity. Insulin
resistance is a key component of the metabolic syndrome [7]
that results in a decrease in fatty acid metabolism in muscle
[42]. Obesity in humans shows a decrease in muscle fatty
acid oxidative capacity leading to increased vastus lateralis
TAG accompanied by decreases in COX and CPT activity
[42]. This differs from cp/cp rats (Table 2) and may reflect
taxa-, muscle- or model-specific differences in the effects of
insulin resistance on mitochondrial gene expression. Differ-
ences seen in cp/cp rats may reflect the combination of loss
of leptin signaling and insulin resistance on muscle respira-
tory gene expression. Loss of insulin sensitivity in strepto-
zotocin-diabetic mice leads to an increase in all of the h-
oxidation enzymes in muscle [35]. The changes in enzyme
stoichiometries seen in this study may reflect interactions
between leptin and insulin signaling pathways. In cp/cp rats,
the obese phenotype does not appear until insulin levels
increase [4], suggesting that insulin signaling is more
important than leptin signaling.
4.3. Hyperlipidemia
Fatty acids are thought to act as signaling molecules and
can activate PPARa [43]. This transcriptional pathway
appears to be disrupted in cp/cp rats leading to variable
increases in synthesis of fatty acid enzymes. In fact, hyper-
lipidemia in this model does not result in a coordinated
increase in mitochondria biogenesis and fatty acid enzymes
that help regulate body composition under normal circum-
stances [44]. Free fatty acids also stimulate insulin secretion
from h-cells [45], which may provide a link between
hyperlipidemia, increased circulatory insulin and insulin
resistance. The hyperlipidemia may also trigger insulin
resistance through activation of the InB kinase-h pathway
and inhibition of the insulin signal cascade [46]. Insulin
deficiencies in rats cause an increase in fatty acid uptake by
muscles [42,47] and this increased uptake may trigger gene
expression for enzymes involved in fatty acid oxidation
[44]. This does not hold true in hearts of cp/cp rats which
show increased accumulation of TAG in response to an
increase in fatty acid supply but does not alter fatty acidoxidation or the activities of key enzymes of lipid metab-
olism do not change (Ref. [8]; Table 2).
4.4. Conclusions and implications
We found that cp/cp rats showed changes in gene
expression culminating in alterations in select enzymes of
fatty acid oxidation in peripheral tissues. It is not clear if
these enzymatic changes contribute to the obese phenotype
or if they are a response to the metabolic changes in cp/cp
rats. It is noteworthy that the obese JCR:LA rats showed
normal or elevated levels of fatty acid oxidation enzymes,
whereas obesity is normally associated with a decrease in
fatty acid oxidation [48,49]. Superimposed upon the enzy-
matic changes are the effects of allosteric regulators (e.g.
malonyl-CoA) that change in response to hormonal and
metabolic conditions. Furthermore, changes in fatty acid
metabolism have the potential to alter the expression of
bioenergetic genes (e.g. UCP-2 and UCP-3 [50]). Our
studies focused on enzymes of intermediary metabolism,
primarily those in mitochondria oxidative metabolism. We
conclude that changes in leptin signaling act indirectly on
the metabolic phenotype, acting through metabolic changes
or insulin resistance. However, it is important to recognize
the potential effects of leptin, both direct and indirect, on
other enzymes related to the uptake, storage and hydrolysis
of lipid in muscle.Acknowledgements
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